Athira Pharma Inc Stock News
$0.38
3.06%
yesterday
Nasdaq,
Aug 11, 10:00 pm CET
Index
Industry
Athira Pharma Inc Stock News
Positive
The Motley Fool
●
5 days ago
Athira Pharma (ATHA -2.38%), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost containment, strategic pipeline refocus, and progress with its lead candidate, ATH-1105.
Neutral
GlobeNewsWire
●
3 months ago
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development
Neutral
GlobeNewsWire
●
3 months ago
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25
Neutral
GlobeNewsWire
●
6 months ago
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
